Apollo Ventures

Apollo Health Ventures is a transatlantic venture capital firm founded in 2016 and headquartered in Berlin, Germany. Co-founded and led by Managing Director Nils Regge, the firm's singular mission is to fund and co-build companies that target the root causes of aging and age-related diseases. Apollo focuses on breakthrough science in Alzheimer's disease, heart disease, cancer, sarcopenia, and frailty — with the ultimate goal of extending healthy human lifespan. The firm takes an active company-building role, frequently co-founding portfolio companies alongside scientists and entrepreneurs. Apollo leads rounds and has made approximately 13 investments across Seed and Series A stages, with seed rounds averaging $9.7 million and Series A rounds averaging $34 million. Notable portfolio companies include Auron Therapeutics, HAYA Therapeutics, Cleara Biotech, Cognito Therapeutics, and Aeovian Pharmaceuticals. The portfolio spans the United States and Europe, reflecting the firm's transatlantic orientation and its Bio Fund I structure. Apollo Health Ventures differentiates itself through its company-building model: the team does not passively invest in existing longevity companies but actively participates in their creation, recruiting scientists, shaping research strategy, and guiding early clinical positioning. This founder-in-residence approach concentrates portfolio expertise in a narrow therapeutic category and allows Apollo to shape the science from the earliest stages — well before most investors enter the conversation.